Coeptis Therapeutics, Inc. (COEP) Year-over-year earnings per share growth for the last twelve months

COEP (Coeptis Therapeutics Inc.) - company brandmark

Quarterly EPS volatility highlights the unstable cash flow of Coeptis Therapeutics (COEP), whose well-being is tied to external financing and clinical trials. The value of 81.50 shows the current level of this metric. The business foundation consists of innovative NK-cell therapies against leukemias and partnerships with pharma behemoths, yet the lack of sales and pre-commercial status make the market value dependent exclusively on scientific achievements.

coeptistx.com (COEP) - Year-over-year earnings per share growth for the last 12 months from 04/28/2023 to 05/09/2026

Analytical breakdowns for Coeptis Therapeutics

- market value and analyst target forecast:
- market capitalization details:
Comprehensive company analysis:Coeptis Therapeutics
Manufactured product of Coeptis Therapeutics

The investment attractiveness of Coeptis Therapeutics (COEP) is determined by its ability to scale developments amidst geopolitical risks and logistical constraints regarding component imports. By analyzing the growth rate of quarterly earnings per share, an investor tracks the net income dynamics over the last three months, which allows for the identification of business efficiency stagnation and prevents capital loss during a slowdown in financial performance.

Competing companies

tgtherapeutics.com (TGTX) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Arcellx Therapeutics (ACLX)|Year-over-year earnings per share growth for the last twelve months Disc Medicine Inc|Earnings per share growth in annualized terms for the last twelve months Syndax Pharmaceuticals SNDX|Quarterly EPS earnings growth KURA|ADC Therapeutics SA - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth FHTX (Foghorn Therapeutics, Inc.)|Vor Bio Inc. (VOR) - Earnings per share growth in annualized terms for the last twelve months|NKTX - Year-over-year earnings per share growth for the last twelve months|Actinium Pharmaceuticals, Inc. (ATNM) - Year-over-year net earnings per share growth for the last 12 months|ESLA (Estrella Immunopharma) - Year-over-year net earnings per share growth for the last 12 months|CASI - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Marker Bio|Quarterly EPS earnings growth IN8bio, Inc.|Year-over-year earnings per share growth for the last twelve months Eterna Therapeutics Inc (ERNA)|Year-over-year net earnings per share change for the last twelve months gtbiopharma.com|Quarterly EPS earnings growth APTO (Aptose Biosciences)|Quarterly EPS earnings growth Bio-Path BPTH|MEI Pharma Inc - Quarterly EPS earnings growth|VINC (Vincerx Pharma Inc.) - Year-over-year earnings per share growth for the last 12 months